U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

Posted on September 30, 2026 by sHq_LoGiNz

PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #CAMZYOS–U.S. FDA Approves Expanded Indication for BMS’s CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients

Posted in UncategorizedTagged Business Wire